エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number: 001-37384
GALAPAGOS NV
(Translation of registrant's name into English)
Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, and 333-275886).
On April 30, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated April 30, 2024
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GALAPAGOS NV | ||
| (Registrant) | ||
| Date: April 30, 2024 | /s/ Annelies Denecker | |
| Annelies Denecker | ||
| Company Secretary | ||
EXHIBIT 99.1
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all
resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024
were approved.
The AGM approved, amongst other items:
The EGM approved, amongst other items:
All documents related to the AGM and EGM can be consulted on our website. The minutes of the meetings will be made available in due course.
About Galapagos
We are a biotechnology company with operations in Europe and the US dedicated
to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize
compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies,
and biologics in oncology and immunology. With capabilities from lab to patient, including a decentralized CAR-T manufacturing network,
we are committed to challenging the status quo and delivering results for our patients, employees and shareholders. For additional information,
please visit www.glpg.com or follow us on LinkedIn or X (formerly Twitter).
For further information, please contact:
| Media inquiries: Marieke Vermeersch +32 479 490 603 media@glpg.com Jennifer Wilson + 44 7539 359 676 media@glpg.com |
Investor inquiries: Sofie Van Gijsel +1 781 296 1143 ir@glpg.com Sandra Cauwenberghs +32 495 58 46 63 ir@glpg.com |
Forward-looking statements
This release may contain forward-looking statements. Such
forward-looking statements are not guarantees of future results. These statements speak only as of the date of publication of this release.
We expressly disclaim any obligation to update any forward-looking statements in this release, unless specifically required by law or
regulation.
Disclaimer
The contents of our website, including the annual report for the financial year
2023 and the reports prepared by the Board of Directors and the statutory auditor at the occasion of the extraordinary shareholders’
meeting, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.